• editor@ijmra.in
  • ISSN[Online] : 2643-9875  ||  ISSN[Print] : 2643-9840

Volume 07 Issue 07 July 2024

The Critical Role of Vitamin D in the Physiological and Immunological Response to a Covaid-19 Infection
Rana N. Abdul Hameed
Door Technical Institute, Northern Technical University
DOI : https://doi.org/10.47191/ijmra/v7-i07-35

Google Scholar Download Pdf
ABSTRACT:

This research can contribute to elucidate this issue, in addition to subsidizing the clinical practice of health professionals and assist in the preparation of specific care protocols for this population, with peculiar clinical characteristics and little discussed in the scope of research. This study aimed to evaluate the results of studies that supplemented with vitamin D, impact of SOD on patients with CKD. Several studies have been done regarding the inhibitory effect of SARS. Mice without VDR expression have a 3-fold increased renin expression with a consequent increase in plasma angiotensin II and, clinically, arterial hypertension. In cell cultures of As 4.1 cells, with high renin synthesis, the administration of 1.25 (OH) 2D markedly decreased the activity of the promoter region of the VDR-mediated renin gene, resulting in a decrease in the respective messenger ribonucleic acid (mRNA). In mice lacking 1  - hydroxylase expression, administration of 1.25 (OH) 2D was also effective in decreasing the activation of RAAS and in the treatment of arterial hypertension. An experimental study with partially nephrectomized animal models evaluated the renal effect of administering an ACE inhibitor, enalapril, a vitamin D analogue, paricalcitol, or both. It was found that in most of the parameters studied, the combination was more effective than either of the two drugs separately.

KEYWORDS:

vitamin D, immunological response, covaid-19 infection

REFERENCES
1) Afshan, F. U., Nissar, B., Chowdri, N. A., & Ganai, B. A. (2021). Relevance of vitamin D3 in COVID-19 infection. Gene Reports, 24, 101270.

2) Annweiler, C., Hanotte, B., de l’Eprevier, C. G., Sabatier, J. M., Lafaie, L., & Célarier, T. (2020). Vitamin D and survival in COVID-19 patients: A quasi-experimental study. The Journal of steroid biochemistry and molecular biology, 204, 105771.

3) Bi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., ... & Feng, T. (2020). Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. The Lancet Infectious Diseases, 20(8), 911-919.

4) Calder, P. C., Carr, A. C., Gombart, A. F., & Eggersdorfer, M. (2020). Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients, 12(4), 1181.

5) Cappellini, F., Brivio, R., Casati, M., Cavallero, A., Contro, E., & Brambilla, P. (2020). Low levels of total and ionized calcium in blood of COVID-19 patients. Clinical Chemistry and Laboratory Medicine (CCLM), 58(9), e171-e173.

6) Cheng, A., Hu, L., Wang, Y., Huang, L., Zhao, L., Zhang, C., ... & Liu, Q. (2020). Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients. International journal of antimicrobial agents, 56(3), 106110.

7) Colafrancesco, S., Alessandri, C., Conti, F., & Priori, R. (2020). COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?. Autoimmunity reviews, 19(7), 102573.

8) Correale, J., Ysrraelit, M. C., & Gaitán, M. I. (2010). Gender differences in 1, 25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. The Journal of Immunology, 185(8), 4948-4958.

9) Crespi, B., & Alcock, J. (2021). Conflicts over calcium and the treatment of COVID-19. Evolution, Medicine, and Public Health, 9(1), 149-156.

10) DeMartino, A. W., Rose, J. J., Amdahl, M. B., Dent, M. R., Shah, F. A., Bain, W., ... & Gladwin, M. T. (2020). No evidence of hemoglobin damage by SARS-CoV-2 infection. Haematologica, 105(12), 2769.

11) Di Filippo, L., Formenti, A. M., Rovere-Querini, P., Carlucci, M., Conte, C., Ciceri, F., ... & Giustina, A. (2020). Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. Endocrine, 68(3), 475-478.

12) Dofferhoff, A. S., Piscaer, I., Schurgers, L. J., Walk, J., van den Ouweland, J. M., Hackeng, T. M., ... & Janssen, R. (2020). Reduced vitamin K status as a potentially modifiable prognostic risk factor in COVID-19.

13) Entrenas Castillo, M., Entrenas Costa, L. M., Vaquero Barrios, J. M., Díaz, J. F. A., Miranda, J. L., Bouillon, R., & Gomez, J. M. Q. (2020). Effect of calcifediol treatment and best available tehrapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J. Steroid Biochem. Mol. Biol, 203, 105751.

14) Faiq, T. N., Ghareeb, O. A., & Fadhel, M. F. (2021). Characteristics and Outcomes of COVID 19 Patients in Kirkuk City, Iraq. Annals of the Romanian Society for Cell Biology, 12432-12438.

15) Ferreira, A. O., Polonini, H. C., & Dijkers, E. C. (2020). Postulated adjuvant therapeutic strategies for COVID-19. Journal of Personalized Medicine, 10(3), 80.

16) Flore, R., Ponziani, F. R., Di Rienzo, T. A., Zocco, M. A., Flex, A., Gerardino, L., ... & Gasbarrini, A. (2013). Something more to say about calcium homeostasis: the role of vitamin K2 in vascular calcification and osteoporosis. Eur Rev Med Pharmacol Sci, 17(18), 2433-2440.

17) Frater, J. L., Zini, G., d’Onofrio, G., & Rogers, H. J. (2020). COVID‐19 and the clinical hematology laboratory. International journal of laboratory hematology, 42, 11-18.

18) Fu, J., Kong, J., Wang, W., Wu, M., Yao, L., Wang, Z., ... & Yu, X. (2020). The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. Thrombosis research, 192, 3-8.

19) Gray, J. C., French, R. R., James, S., Al‐Shamkhani, A., Johnson, P. W., & Glennie, M. J. (2008). Optimising anti‐tumour CD8 T‐cell responses using combinations of immunomodulatory antibodies. European journal of immunology, 38(9), 2499-2511.

20) Guan, W. J., Liang, W. H., Zhao, Y., Liang, H. R., Chen, Z. S., Li, Y. M., ... & He, J. X. (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. European Respiratory Journal, 55(5).

21) Han, Y., Zhang, H., Mu, S., Wei, W., Jin, C., Tong, C., ... & Gu, G. (2020). Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY), 12(12), 11245.

22) Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., ... & Weinberger, T. (2020). Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. Journal of Allergy and Clinical Immunology, 146(1), 128-136.

23) Honce, R., & Schultz-Cherry, S. (2019). Impact of obesity on influenza A virus pathogenesis, immune response, and evolution. Frontiers in immunology, 10, 1071.

24) Honce, R., & Schultz-Cherry, S. (2019). Impact of obesity on influenza A virus pathogenesis, immune response, and evolution. Frontiers in immunology, 10, 1071.

25) Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223), 497-506.

26) Huang, I., Pranata, R., Lim, M. A., Oehadian, A., & Alisjahbana, B. (2020). C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Therapeutic advances in respiratory disease, 14, 1753466620937175.

27) Huang, I., Pranata, R., Lim, M. A., Oehadian, A., & Alisjahbana, B. (2020). C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Therapeutic advances in respiratory disease, 14, 1753466620937175.

28) Hussein, A. M., Taha, Z. B., Malek, A. G., Rasul, K. A., Hazim, D. Q., Ahmed, R. J., & Mohamed, U. B. (2021). D-dimer and serum ferritin as an independent risk factor for severity in COVID-19 patients. Materials Today: Proceedings.

29) Jakhmola, S., Baral, B., & Jha, H. C. (2021). A comparative analysis of COVID-19 outbreak on age groups and both the sexes of population from India and other countries. The Journal of Infection in Developing Countries, 15(03), 333-341.

30) Kaushal, K., Kaur, H., Sarma, P., Bhattacharyya, A., Sharma, D. J., Prajapat, M., Pathak, M., Kothari, A., Kumar, S., Rana, S., Kaur, M., Prakash, A., Mirza, A. A., Panda, P. K., Vivekanandan, S., Omar, B. J., Medhi, B., & Naithani, M. (2022). Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. Journal of critical care, 67, 172–181. https://doi.org/10.1016/j.jcrc.2021.09.023

31) Kelly, A., & Levine, M. A. (2013). Hypocalcemia in the critically ill patient. Journal of intensive care medicine, 28(3), 166-177.

32) Kernan, K. F., & Carcillo, J. A. (2017). Hyperferritinemia and inflammation. International immunology, 29(9), 401-409.

33) Kimura, H., Francisco, D., Conway, M., Martinez, F. D., Vercelli, D., Polverino, F., ... & Kraft, M. (2020). Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. Journal of Allergy and Clinical Immunology, 146(1), 80-88.

34) Komolafe, O., Pereira, S. P., Davidson, B. R., & Gurusamy, K. S. (2017). Serum C‐reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis. Cochrane Database of Systematic Reviews, (4).

35) Koozi, H., Lengquist, M., & Frigyesi, A. (2020). C-reactive protein as a prognostic factor in intensive care admissions for sepsis: a Swedish multicenter study. Journal of critical care, 56, 73-79.

36) Kulcsar, K. A., Coleman, C. M., Beck, S. E., & Frieman, M. B. (2019). Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI insight, 4(20).

37) Lami, F.; Rashak, H.A.; Khaleel, H.A.; Mahdi, S.G.; Adnan, F. et al.,( 2021). Iraq experience in handling the COVID-19 pandemic: implications of public health challenges and lessons learned for future epidemic preparedness planning. Journal of Public Health | pp. 1–10.

38) Leaf, D. E., & Ginde, A. A. (2021). Vitamin D3 to treat COVID-19: different disease, same answer. Jama, 325(11), 1047-1048.

39) Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., ... & Wu, J. (2020). Coronavirus infections and immune responses. Journal of medical virology, 92(4), 424-432.

40) Li, H., Xiang, X., Ren, H., Xu, L., Zhao, L., Chen, X., ... & Wu, Q. (2020). SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19). The Journal of Infection.Lin, L., Lu, L., Cao, W., & Li, T. (2020). Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerging microbes & infections, 9(1), 727-732.

41) Liu, F., Li, L., Xu, M., Wu, J., Luo, D., Zhu, Y., ... & Zhou, X. (2020). Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. Journal of Clinical Virology, 127, 104370.

42) Malaguarnera, L. (2020). Vitamin D3 as potential treatment adjuncts for COVID-19. Nutrients, 12(11), 3512.

43) Mo, P., Xing, Y., Xiao, Y., Deng, L., Zhao, Q., Wang, H., ... & Zhang, Y. (2021). Clinical characteristics of refractory coronavirus disease 2019 in Wuhan, China. Clinical infectious diseases, 73(11), e4208-e4213.

44) Moon, T. S., Fox, P. E., Somasundaram, A., Minhajuddin, A., Gonzales, M. X., Pak, T. J., & Ogunnaike, B. (2019). The influence of morbid obesity on difficult intubation and difficult mask ventilation. Journal of anesthesia, 33(1), 96-102.

45) Muscogiuri, G., Barrea, L., Somma, C. D., Laudisio, D., Salzano, C., Pugliese, G., ... & Savastano, S. (2019). Sex differences of vitamin D status across BMI classes: An observational prospective cohort study. Nutrients, 11(12), 3034.

46) Orme, R. P., Middleditch, C., Waite, L., & Fricker, R. A. (2016). The role of vitamin D3 in the development and neuroprotection of midbrain dopamine neurons. Vitamins & Hormones, 100, 273-297.

47) Pagano, M. T., Peruzzu, D., Ruggieri, A., Ortona, E., & Gagliardi, M. C. (2020). Vitamin D and sex differences in COVID-19. Frontiers in endocrinology, 11, 567824.

48) Panagiotou, G., Tee, S. A., Ihsan, Y., Athar, W., Marchitelli, G., Kelly, D., ... & Quinton, R. (2020). Low serum 25-hydroxyvitamin D (25 [OH] D) levels in patients hospitalised with COVID-19 are associated with greater disease severity: Results of a local audit of practice. medRxiv.

49) Prietl, B., Pilz, S., Wolf, M., Tomaschitz, A., Obermayer-Pietsch, B., Graninger, W., & Pieber, T. R. (2010). Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases?. The Israel Medical Association journal: IMAJ, 12(3), 136-139.

50) Robert Koch Institute. (2020). Coronavirus disease 2019 (COVID-19): Daily situation report of the Robert Koch Institute.

51) Sanghera, D. K., Sapkota, B. R., Aston, C. E., & Blackett, P. R. (2017). Vitamin D status, gender differences, and cardiometabolic health disparities. Annals of Nutrition and Metabolism, 70(2), 79-87.

52) Serrano-Lorenzo, P., Coya, O. N., López-Jimenez, A., Blázquez, A., Delmiro, A., Lucia, A., ... & de Miguel-Reyes, M. (2021). Plasma LDH: A specific biomarker for lung affectation in COVID-19?. Practical laboratory medicine, 25, e00226.

53) Severin, R., Arena, R., Lavie, C. J., Bond, S., & Phillips, S. A. (2020). Respiratory muscle performance screening for infectious disease management following COVID-19: a highly pressurized situation. The American journal of medicine, 133(9), 1025-1032.

54) Siddiqi, H. K., & Mehra, M. R. (2020). COVID-19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal. The Journal of Heart and Lung Transplantation, 39(5), 405.

55) Silberstein, M. (2020). Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?. Medical hypotheses, 140, 109767.

56) Soeroto, A. Y., Soetedjo, N. N., Purwiga, A., Santoso, P., Kulsum, I. D., Suryadinata, H., & Ferdian, F. (2020). Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14(6), 1897-1904.

57) Sood, A. (2009). Altered resting and exercise respiratory physiology in obesity. Clinics in chest medicine, 30(3), 445-454.

58) Spanier, J. A., Nashold, F. E., Mayne, C. G., Nelson, C. D., & Hayes, C. E. (2015). Vitamin D and estrogen synergy in Vdr-expressing CD4+ T cells is essential to induce Helios+ FoxP3+ T cells and prevent autoimmune demyelinating disease. Journal of neuroimmunology, 286, 48-58.

59) Sproston, N. R., & Ashworth, J. J. (2018). Role of C-reactive protein at sites of inflammation and infection. Frontiers in immunology, 9, 754.

60) Stringer, D., Braude, P., Myint, P. K., Evans, L., Collins, J. T., Verduri, A., ... & Carter, B. (2021). The role of C-reactive protein as a prognostic marker in COVID-19. International journal of epidemiology, 50(2), 420-429.

61) Van Wilpe, S., Koornstra, R., Den Brok, M., De Groot, J. W., Blank, C., De Vries, J., ... & Mehra, N. (2020). Lactate dehydrogenase: a marker of diminished antitumor immunity. Oncoimmunology, 9(1), 1731942.

62) WHO. (2020). Available from: http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi (2020)

63) Wu, M. Y., Yao, L., Wang, Y., Zhu, X. Y., Wang, X. F., Tang, P. J., & Chen, C. (2020). Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. Respiratory Research,2(1),1-6.

64) Xu, J., Yang, J., Chen, J., Luo, Q., Zhang, Q., & Zhang, H. (2017). Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Molecular medicine reports, 16(5), 7432-7438.

65) Yang, C., Ma, X., Wu, J., Han, J., Zheng, Z., Duan, H., ... & Dong, L. (2021). Low serum calcium and phosphorus and their clinical performance in detecting COVID‐19 patients. Journal of medical virology, 93(3), 1639-1651.

66) Yasuda, K., Takeuchi, Y., & Hirota, K. (2019, May). The pathogenicity of Th17 cells in autoimmune diseases. In Seminars in immunopathology (Vol. 41, No. 3, pp. 283-297). Springer Berlin Heidelberg.

67) Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., ... & Zhang, S. (2020). The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clinical Immunology, 214, 108393.

68) Zheng, F., Liao, C., Fan, Q. H., Chen, H. B., Zhao, X. G., Xie, Z. G., ... & Jin, R. M. (2020). Clinical characteristics of children with coronavirus disease 2019 in Hubei, China. Current medical science, 40(2), 275-280.

69) Zheng, Y., Sun, L., Jiang, T., Zhang, D., He, D., & Nie, H. (2014). TNFα promotes Th17 cell differentiation through IL-6 and IL-1β produced by monocytes in rheumatoid arthritis. Journal of immunology research, 2014.

70) Zhou, X., Chen, D., Wang, L., Zhao, Y., Wei, L., Chen, Z., & Yang, B. (2020). Low serum calcium: a new, important indicator of COVID-19 patients from mild/moderate to severe/critical. Bioscience reports,40(12).

71) Zivin, J. R., Gooley, T., Zager, R. A., & Ryan, M. J. (2001). Hypocalcemia: a pervasive metabolic abnormality in the critically ill. American journal of kidney diseases, 37(4),689-698.
Volume 07 Issue 07 July 2024

There is an Open Access article, distributed under the term of the Creative Commons Attribution – Non Commercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits remixing, adapting and building upon the work for non-commercial use, provided the original work is properly cited.


Our Services and Policies

Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not conform to the format and style of the Journal may be returned to the authors for revision or rejected.

The Journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication so that it conforms to the formatting requirements of the Journal.

International Journal of Multidisciplinary Research and Analysis will publish 12 monthly online issues per year,IJMRA publishes articles as soon as the final copy-edited version is approved. IJMRA publishes articles and review papers of all subjects area.

Open access is a mechanism by which research outputs are distributed online, Hybrid open access journals, contain a mixture of open access articles and closed access articles.

International Journal of Multidisciplinary Research and Analysis initiate a call for research paper for Volume 07 Issue 11 (November 2024).

PUBLICATION DATES:
1) Last Date of Submission : 26 November 2024 .
2) Article published within a week.
3) Submit Article : editor@ijmra.in or Online

Why with us

International Journal of Multidisciplinary Research and Analysis is better then other journals because:-
1 : IJMRA only accepts original and high quality research and technical papers.
2 : Paper will publish immediately in current issue after registration.
3 : Authors can download their full papers at any time with digital certificate.

The Editors reserve the right to reject papers without sending them out for review.

Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not conform to the format and style of the Journal may be returned to the authors for revision or rejected. The Journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication so that it conforms to the formatting requirements of the Journal.

Indexed In
Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar